Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2023
Reporting Period: Third Quarter ended September 30, 2023
Business Context: The filing serves as a notification that the Company issued a press release announcing its financial results for the quarter ended September 30, 2023, and providing a corporate update.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained in the referenced press release (Exhibit 99.1), which is not included in the input text. Therefore, no specific financial metrics can be extracted from this document.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only indicates that such results were announced in the accompanying press release.
Guidance, Outlook, and Risks
Management Commentary: The filing references a corporate update included in the press release but does not detail the content of that update.
Legal Disclaimer: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to obtain specific Q3 2023 financial results.
- Verify the specific details of the "Corporate Update" mentioned in the press release title.
- Confirm the Company's cash position and runway based on the detailed financial statements referenced in the press release.
- Check for any new clinical trial milestones or regulatory updates included in the corporate update.